A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)

Inclusion Criteria: * Willingness to provide signed Informed Consent Form * Age ≥ 18 years * For sexually active women of childbearing potential, use of an appropriate form of contraception (or abstinence) for the duration of the study * Ability and willingness to return for all scheduled visits and assessments Ocular Inclusion Criterion (Study Eye): * Foveal center-involved macular edema secondary to BRVO * BCVA using ETDRS charts of 20/40 to 20/400 (Snellen equivalent) * Mean central subfield thickness ≥ 250 μm on two optical coherence tomography (OCT) measurements (at screening \[confirmed by the central reading center\] and Day 0 \[confirmed by the evaluating physician\]) * Media clarity, pupillary dilation, and participant cooperation sufficient to obtain adequate fundus photographs Exclusion Criteria: * History of cerebral vascular accident or myocardial infarction within 3 months prior to Day 0 * History of any anti-vascular endothelial growth factor (VEGF) treatment in fellow eye within 3 months prior to Day 0 * History of any systemic anti-VEGF or pro-VEGF treatment within 6 months prior to Day 0 * History of allergy to fluorescein * History of allergy to ranibizumab injection or related molecule * Relevant systemic disease that may be associated with increased systemic VEGF levels (namely, all active malignancies); history of successfully treated malignancies is not an exclusion criterion * Uncontrolled blood pressure * Pregnancy or lactation * Any condition th…